10,640 results match your criteria Nephritis Lupus


Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus.

Pak J Med Sci 2019 Jan-Feb;35(1):86-89

Dr. Ammad Asghar, FCPS (Medicine), PGR Rheumatology, Department of Rheumatology, Sheikh Zayed Hospital, Lahore, Pakistan.

Objective: To determine the frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus in a Pakistani population, presenting at a tertiary care hospital.

Methods: This cross-sectional study was conducted at the Department of Rheumatology, Shiekh Zayed Hospital, Lahore from March to June 2018. A total of 97 patients, who fulfilled the Systemic Lupus Erythematosus (SLE) criteria of American College of Rheumatology (ACR) 1992 were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12669/pjms.35.1.405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408637PMC

Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.

Drug Des Devel Ther 2019 12;13:857-869. Epub 2019 Mar 12.

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou 515041, China,

Background: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis.

Methods: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C levels, C levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S189156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420100PMC

Clinical efficacy and safety of rituximab in lupus nephritis.

Drug Des Devel Ther 2019 11;13:845-856. Epub 2019 Mar 11.

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China,

Background: Long-term treatment programs with low toxicity represent a therapeutic challenge in lupus nephritis (LN). Although a therapeutic benefit of rituximab (RTX) has been reported in LN patients who have failed conventional treatment, the results are controversial. We aimed to assess the clinical efficacy and safety of RTX as a new immunosuppressive medicine in the treatment of LN with a meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S195113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417005PMC
March 2019
1 Read

Clinical Outcomes and Clinico-pathological Correlations in Lupus Nephritis with Kidney Biopsy showing Thrombotic Microangiopathy.

J Rheumatol 2019 Mar 15. Epub 2019 Mar 15.

From the Division of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Division of Nephrology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong 3Department of Pathology, Queen Mary Hospital, Hong Kong. Address correspondence to Professor Tak Mao Chan, Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, The University of Hong Kong, Hong Kong, Email: or Professor Xue-mei Li, Department of Nephrology, Peking Union Medical College Hospital, NO.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China. Email:

Objective: Renal thrombotic microangiopathy (TMA) is an uncommon pathological finding in lupus nephritis (LN), and its clinical significance remains to be defined.

Methods: 24 patients with lupus nephritis (LN) and renal TMA were selected from a retrospective review of 677 biopsy-proven LN patients, and compared with 48 LN Controls without TMA (in 1:2 ratio) matched according to demographics and treatments.

Results: Renal TMA was noted in 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180773DOI Listing

The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target.

Expert Rev Clin Immunol 2019 Mar 15. Epub 2019 Mar 15.

c Division of Rheumatology and Clinical Immunology, Department of Medicine , Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , United States.

Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1744666X.2019.1
Publisher Site
http://dx.doi.org/10.1080/1744666X.2019.1593141DOI Listing
March 2019
2 Reads

Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations.

Sci Rep 2019 Mar 14;9(1):4530. Epub 2019 Mar 14.

Centre de Recherche du CHU de Québec - Université Laval, Département de microbiologie et immunologie, Faculté de Médecine de l'Université Laval, Québec, Qc, Canada.

Mitochondria are organelles that govern energy supply and control cell death. Mitochondria also express bacterial features, such as the presence of inner membrane cardiolipin and a circular genome rich in hypomethylated CpG motifs. While mitochondrial extrusion by damaged organs or activated cells is thought to trigger innate immunity, it is unclear whether extracellular mitochondria also stimulate an adaptive immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40900-3DOI Listing
March 2019
1 Read

Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.

Lupus 2019 Mar 14:961203319836712. Epub 2019 Mar 14.

1 Department of Women and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Background: Juvenile-onset systemic lupus erythematosus (JSLE) is more severe than adult-onset disease, including more lupus nephritis (LN). Despite differences in phenotype/pathogenesis, treatment is based upon adult trials. This study aimed to compare treatment response, damage accrual, time to inactive LN and subsequent flare, in JSLE LN patients treated with mycophenolate mofetil (MMF) versus intravenous cyclophosphamide (IVCYC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319836712DOI Listing
March 2019
2 Reads

Increased Serum Levels of Soluble B7-H4 in Patients with Systemic Lupus Erythematosus.

Iran J Immunol 2019 Mar;16(1):43-52

Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Background: Members of B7 family are reported to regulate lymphocytes activation, transmit both costimulatory and co-inhibitory signals, control T cell-mediated immune responses and tolerance. Among which B7-H4 is reported to regulate the immune response negatively.

Objective: To investigate the plasma concentration of soluble B7-H4 (sB7-H4) and its clinical significance in systemic lupus erythematosus (SLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22034/IJI.2019.39405DOI Listing
March 2019
4 Reads

O6 gastroenteritis in a patient with lupus nephritis - a report from coastal Karnataka, South India.

JMM Case Rep 2019 Jan 19;6(1):e005171. Epub 2018 Dec 19.

Enteric Diseases Division, Central Research Lab, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.

Introduction: O1 strains are responsible for pandemics of cholera and major epidemics in the world. All the remaining non-O1/non-O139 strains are less virulent and are responsible for sporadic cases of gastroenteritis. These non-O1/non-O139 serogroups have more than 200 somatic antigens, and mostly lack cholera toxin and toxin co-regulated pilus encoding genes. Read More

View Article

Download full-text PDF

Source
http://www.microbiologyresearch.org/content/journal/jmmcr/10
Publisher Site
http://dx.doi.org/10.1099/jmmcr.0.005171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412036PMC
January 2019
2 Reads

Impact of functional IL-18 polymorphisms on genetic predisposition and diverse clinical manifestations of the disease in Indian SLE patients.

Lupus 2019 Mar 11:961203319834677. Epub 2019 Mar 11.

1 National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, India.

Several studies have demonstrated associations between interleukin-18 polymorphisms and risk of systemic lupus erythematosus in different populations except one of Indian origin. We therefore investigated for the influence of interleukin-18 (-1297T/C, -607A/C, -137G/C; + 105A/C) polymorphisms on genetic susceptibility and clinical expression of the disease in Indian systemic lupus erythematosus patients. A total of 200 systemic lupus erythematosus patients and 201 controls were recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319834677DOI Listing
March 2019
2 Reads

Proteomic profiling of urine: implications for lupus nephritis.

Expert Rev Proteomics 2019 Mar 11:1-11. Epub 2019 Mar 11.

b Division of Nephrology & Hypertension, Department of Pediatrics , University of Cincinnati College of Medicine , Cincinnati , OH , USA.

Introduction: Lupus nephritis (LN) is a common and significant manifestation, affecting 60% of adults and 80% of children with systemic lupus erythematosus, with up to 30% of patients progressing to end stage renal disease. There remains an unmet need for non-invasive markers of disease activity, damage, and response to therapy. In addition, non-invasive biomarkers that predict therapeutic efficacy are needed to enable cost-effective clinical trials of novel agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2019.1592681DOI Listing
March 2019
1 Read

Refractory lupus nephritis: When, why and how to treat.

Autoimmun Rev 2019 Mar 4. Epub 2019 Mar 4.

Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Hills Road, CB2 0QQ, Cambridge, Cambridge University Hospitals, United Kingdom; Department of Medicine, University of Cambridge, CB2 0QQ Cambridge, United Kingdom. Electronic address:

Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response, proteinuria and renal function, that do not discriminate clearly between activity and irreversible damage. Understanding the causes of refractory disease and developing treatment strategies is important because these patients are more likely to develop poor outcomes, especially end stage renal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2019.03.004DOI Listing
March 2019
1 Read

[Lupus nephritis].

Internist (Berl) 2019 Mar 6. Epub 2019 Mar 6.

Medizinische Klinik III (Nephrologie, Hypertensiologie, Rheumatologie), Sana Klinikum Offenbach GmbH, KfH-Nierenzentrum Offenbach, Starkenburgring 66-70, 63069, Offenbach, Deutschland.

Lupus nephritis (LN) is the most frequent and one of the most severe organ manifestations of systemic lupus erythematosus. The central pathogenetic mechanism is characterized by the loss of immune tolerance against autoantigens of the cell nucleus, which can lead to renal inflammation via the formation of nuclear autoantibodies. The clinical manifestations of LN encompass nephritic syndrome with the special form of rapidly progressive glomerulonephritis, nephrotic syndrome and thrombotic microangiopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0574-yDOI Listing
March 2019
1 Read

Oncogenes and inflammasomes in lupus nephritis.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 5. Epub 2019 Mar 5.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0194-xDOI Listing
March 2019
1 Read

Spectrum of biopsy proven renal disease in northern India: a single centre study.

Nephrology (Carlton) 2019 Mar 4. Epub 2019 Mar 4.

Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India-110029.

Aim: Pattern of kidney diseases varies across geographies due to multiple factors. There is a paucity of information from South Asia due to absence of nationwide/regional biopsy registries. This study aimed to delineate the spectrum of renal parenchymal diseases in our region. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/nep.13582
Publisher Site
http://dx.doi.org/10.1111/nep.13582DOI Listing
March 2019
9 Reads

Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus.

Adv Rheumatol 2019 Mar 4;59(1):10. Epub 2019 Mar 4.

Rheumatology Department, Helwan University Hospital, Helwan, Egypt.

Introduction: Anti-nucleosome and anti-C1q antibodies demonstrated an association with the development of glomerulonephritis in systemic lupus erythematosus (SLE). Some investigators have proposed that monitoring anti-C1q and anti-nucleosome antibodies might be valuable for making predictions about lupus nephritis (LN) and assessment of disease activity as a non-invasive biological marker of renal disease.

Objectives: The current study was proposed to investigate the presence of anti-C1q and anti-nucleosome antibodies in the sera of Egyptian patients with SLE and their association with LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-019-0054-zDOI Listing
March 2019
1 Read

Improvement of outcomes in patients with lupus nephritis: management evolution in Chinese patients from 1994 to 2010.

J Rheumatol 2019 Mar 1. Epub 2019 Mar 1.

From the National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; IBM Research-China, Beijing, China. Funding: This research was funded by the National Key Technology R&D Program (2015BAI12B05) and the National Key Research and Development Program (2016YFC0904100) by the Ministry of Science and Technology of the People's Republic of China. Address correspondence to Prof. Zhi-Hong Liu, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China. Phone: 86-25-84801992. E-mail:

Objective: To assess how the long-term outcomes has changed over the past decades in Chinese patients with lupus nephritis (LN). The trends in patient manifestation at presentation, treatment pattern and therapeutic effects were evaluated.

Methods: A cohort of biopsy-proven LN patients (n=1945) from January 1994 to December 2010 was analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180145DOI Listing

Prediction of free mycophenolic acid concentrations and free fraction in adult lupus nephritis patients.

Ther Drug Monit 2019 Feb 26. Epub 2019 Feb 26.

Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000620DOI Listing
February 2019
1 Read

Systemic Lupus Erythematosus and Myasthenia Gravis: A Rare Association.

Indian J Nephrol 2019 Jan-Feb;29(1):62-64

Department of Nephrology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India.

Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are two autoimmune diseases that have a higher incidence in young females, relapsing-remitting course, and positive antinuclear antibodies. SLE and MG are two different clinical syndromes, which can coexist or precede each other; however, their occurrence in the same patient is rare. We report a 38-year-old female with biopsy-proven lupus nephritis on steroids and cyclophosphamide, later developed MG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_12_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375012PMC
March 2019
1 Read

Anti-α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients.

Lupus 2019 Mar;28(3):365-370

1 Department of Laboratory Medicine, Sun Yat-sen University affiliated Zhongshan Hospital, Zhongshan, China.

Objective: Anti-α-enolase antibody (Ab) combined with β2 microglobulin (β2-MG) were investigated to predict the incidence of nephritis in systemic lupus erythematosus (SLE) patients.

Methods: Levels of serum anti-α-enolase Ab and urinary β2-MG were detected in 115 SLE patients, 29 SLE patients with nephritis and 70 healthy controls by ELISA and immunoturbidimetry, respectively. Furthermore, the correlation between anti-α-enolase Ab combined with β2-MG and the incidence of nephritis in SLE patients was evaluated by correlation analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319828822DOI Listing
March 2019
1 Read

Commentary on the Current Guidelines for the Diagnosis of Lupus Nephritis Flare.

Curr Rheumatol Rep 2019 Feb 27;21(4):12. Epub 2019 Feb 27.

Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Purpose Of Review: Lupus nephritis flare is a frequent complication in patients with systemic lupus erythematosus. Recognizing disease activity is crucial in lupus nephritis management. Proteinuria magnitude and urine sediment change are major clinical indicators of lupus nephritis activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-019-0809-xDOI Listing
February 2019

Protective role of anti-ribosomal P antibody in patients with lupus nephritis.

Int J Rheum Dis 2019 Feb 27. Epub 2019 Feb 27.

Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Korea.

Aim: The aim of this study was to define clinical, histopathologic, and prognostic differences according to the presence of anti-ribosomal P antibody (anti-P) in Korean patients with biopsy-proven lupus nephritis (LN).

Methods: We studied 79 patients who underwent kidney biopsies prior to the start of induction treatment, and who were subsequently treated with immunosuppressive drugs for at least 6 months and followed-up for more than 6 months. Anti-P was measured by immunoblot analysis at the time of renal biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13517DOI Listing
February 2019

Cytosolic Sensors of Viral RNA Are Involved in the Production of Interleukin-6 via Toll-Like Receptor 3 Signaling in Human Glomerular Endothelial Cells.

Kidney Blood Press Res 2019 Feb 22;44(1):62-71. Epub 2019 Feb 22.

Department of Pediatrics, Hirosaki University Hospital, Hirosaki,

Background/aims: Dysregulation of interleukin-6 (IL-6) production in residual renal cells may play a pivotal role in the development of glomerulonephritis (GN). Given that Toll-like receptor 3 (TLR3) signaling has been implicated in the pathogenesis of some forms of GN, we examined activated TLR3-mediated IL-6 signaling in cultured normal human glomerular endothelial cells (GECs).

Methods: We treated GECs with polyinosinic-polycytidylic acid (poly IC), an authentic double-stranded RNA, and analyzed the expression of IL-6 and the cytosolic viral RNA sensors retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation associated gene 5 (MDA5) using reverse transcription quantitative real-time polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000498837DOI Listing
February 2019
1 Read

Renal Outcomes of Pregnant Patients with Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis.

Am J Nephrol 2019 26;49(3):214-224. Epub 2019 Feb 26.

Background: Is the prognosis of immunoglobulin A nephropathy (IgAN) influenced by pregnancy and delivery? The answer to this question still remains to be a controversial topic. Here, we undertook a systematic review and meta-analysis to obtain the overall estimate of potential effect of IgAN and pregnancy on each other.

Methods: We systematically searched MEDLINE, EMBASE, Chinese Biological Medicine and Cochrane for cohort and case-control studies; a total of 1,378 articles were reviewed and 9 studies were included in the end. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496410DOI Listing
February 2019
1 Read

New Attempts to Define and Clarify Lupus.

Curr Rheumatol Rep 2019 Feb 26;21(4):11. Epub 2019 Feb 26.

Medical Genomics, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Av de la Ilustración 114, PTS, 18016, Granada, Spain.

Purpose Of Review: The purpose is to discuss the advances that genetics and genomics have provided to better understand the molecular mechanisms behind SLE and how to solve its heterogeneity. I propose new ideas that can help us stratify lupus in order to find the best therapies for each patient, and the idea of substituting clinical diagnosis with molecular diagnosis according to their molecular patterns, an idea that may not only include lupus but also other diseases.

Recent Findings: The study of rare mutations may provide insight into groups of lupus patients where type I interferon signature is important and help understand those with an atypical clinical presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-019-0810-4DOI Listing
February 2019

ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis.

Rheumatol Int 2019 Feb 26. Epub 2019 Feb 26.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

We investigated the association of antineutrophil cytoplasmic antibody (ANCA) positivity with lupus nephritis (LN) activity, histological features and prognosis in Korean patients with biopsy-proven LN having the results of both myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3)-ANCA. We retrospectively reviewed the medical records of 91 LN patients having the results of ANCA. We divided patients with LN into the two groups according to the ANCA positivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-019-04263-2DOI Listing
February 2019
1 Read

A20 overexpression exerts protective effects on podocyte injury in lupus nephritis by downregulating UCH-L1.

J Cell Physiol 2019 Feb 25. Epub 2019 Feb 25.

Department of Nephrology, Xuzhou Central Hospital, Medical College of Southeast University, Xuzhou, Jiangsu, China.

Lupus nephritis (LN), an autoimmune kidney disease caused by systemic lupus erythematosus (SLE), is the inflammation of the kidney. Although the treatment of LN is still a therapeutic challenge for many practitioners, the present study aims to provide a new insight for the treatment and management. The study aims to explore the effect of A20 on LN in relation to the nuclear factor-kappa B (NF-κB) signaling pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28282DOI Listing
February 2019
2 Reads

Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis.

Int J Pediatr Adolesc Med 2018 Sep 9;5(3):99-102. Epub 2018 Aug 9.

Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Background: Children with lupus nephritis particularly, diffuse proliferative and membranous glomerulonephritis, may necessitate potent immunosuppressive medications and occasionally combined therapy.

Objective: To report the beneficial effects of tacrolimus (TAC) in children with refractory lupus nephritis from a single tertiary pediatric rheumatology clinic.

Methods: This is a retrospective case series of children with refractory lupus nephritis treated with TAC after failure of aggressive immunosuppressive treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpam.2018.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363263PMC
September 2018
2 Reads

Incidence of pediatric glomerular diseases in Arab world: A systematic review.

Saudi J Kidney Dis Transpl 2019 Jan-Feb;30(1):15-23

Department of Allied Health Sciences, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Sultanate of Oman.

Despite the high number of Arab children, there are a scanty available data about different types of pediatric glomerular diseases in all Arab countries. Very few Arab countries have a national renal biopsy registry. In this review, we performed a systematic review analyzing the incidence of pediatric glomerular disease in all Arab countries. Read More

View Article

Download full-text PDF

Source
February 2019
3 Reads

Paraneoplastic systemic lupus erythematosus associated with colorectal cancer.

Oxf Med Case Reports 2019 Feb 16;2019(2):omy131. Epub 2019 Feb 16.

Department of Nephrology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

A 64-year-old gentleman initially presented with nephrotic syndrome and membranous nephropathy with positive staining for C1q, which was suspicious for lupus membranous nephritis. Investigation led to the simultaneous diagnosis of colorectal cancer (CRC). The CRC was surgically excised and the patient's nephrotic syndrome resolved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omy131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380531PMC
February 2019
1 Read

Not only disease activity but also chronic hypertension and overweight are determinants of pregnancy outcomes in patients with systemic lupus erythematosus.

Lupus 2019 Feb 24:961203319832097. Epub 2019 Feb 24.

1 Department of Nephrology, Hypertension and Dialysis, Hospices Civils de Lyon, Lyon, France.

Introduction: Pregnancies in women with lupus nephritis are at high-risk of complications, while scarcity of scientific knowledge on prognostic factors impedes a fair medical counseling. We aimed to identify determinants associated with maternal and fetal complications.

Materials: We retrospectively reviewed medical charts of pregnancies that lasted more than 22 weeks in 66 patients with pre-existing lupus nephritis between 2004 and 2013 in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319832097DOI Listing
February 2019
1 Read

Pim-1 as a therapeutic target in human lupus nephritis.

Arthritis Rheumatol 2019 Feb 21. Epub 2019 Feb 21.

Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.

Objective: Lupus nephritis (LN) is a major determinant of morbidity and mortality in systemic lupus erythematosus (SLE). Pim-1 regulates lymphocyte proliferation and activation. The role of Pim-1 in autoimmune disease remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40863DOI Listing
February 2019

Innate lymphoid cells are increased in systemic lupus erythematosus.

Clin Exp Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

The First Affiliated Hospital of Zhengzhou University, Henan, China.

Objectives: Innate lymphoid cells (ILCs) are emerging mediators of immunity and accumulation of inflammatory ILC populations can occur in inflammatory-mediated conditions. We aimed to examine the proportion of different subgroups of ILCs in the peripheral blood of patients with systemic lupus erythematosus (SLE) to evaluate the pathogenesis of SLE.

Methods: Peripheral blood mononuclear cells were collected from 51 SLE patients and 26 healthy controls. Read More

View Article

Download full-text PDF

Source
February 2019
5 Reads

miR-152 Attenuates the Severity of Lupus Nephritis Through the Downregulation of Macrophage Migration Inhibitory Factor (MIF)-Induced Expression of COL1A1.

Front Immunol 2019 6;10:158. Epub 2019 Feb 6.

Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

The role of miR-152 in lupus nephritis has not been elucidated. The aim of this study was to investigate the role of miR-152 in the pathogenesis of lupus nephritis (LN). miR-152 expression was detected using RT-PCR in LN tissue and normal controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372555PMC
February 2019
2 Reads

Acquired Protein S Deficiency in a Patient with Lupus Nephritis.

Saudi J Med Med Sci 2019 Jan-Apr;7(1):51-52. Epub 2018 Dec 14.

Department of Nephrology, La Rabta Hospital, Tunis, Tunisia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sjmms.sjmms_22_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381849PMC
December 2018

Analysis of expression levels of IL-17 and IL-34 and influencing factors for prognosis in patients with lupus nephritis.

Exp Ther Med 2019 Mar 14;17(3):2279-2283. Epub 2019 Jan 14.

Department of Nephrology, Yanan University Affiliated Hospital, Yanan, Shaanxi 716000, P.R. China.

Expression levels of interleukin-17 (IL-17) and IL-34 was investigated to analyze the influencing factors for prognosis in patients with lupus nephritis (LN). Clinical data of 45 patients (LN group) treated and diagnosed with LN via renal biopsy in Yanan University Affiliated Hospital from October 2010 to October 2012 and 50 healthy subjects (control group) were analyzed retrospectively. Levels of serum IL-17 and IL-34 were detected via enzyme-linked immunosorbent assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364195PMC
March 2019
1 Read

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.

Ann Rheum Dis 2019 Feb 19. Epub 2019 Feb 19.

Department of Medicine, New York University School of Medicine, New York, New York, USA

Background/purpose: To search for a transmissible agent involved in lupus pathogenesis, we investigated the faecal microbiota of patients with systemic lupus erythematosus (SLE) for candidate pathobiont(s) and evaluated them for special relationships with host immunity.

Methods: In a cross-sectional discovery cohort, matched blood and faecal samples from 61 female patients with SLE were obtained. Faecal 16 S rRNA analyses were performed, and sera profiled for antibacterial and autoantibody responses, with findings validated in two independent lupus cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214856DOI Listing
February 2019
1 Read

Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.

Clin Rheumatol 2019 Feb 18. Epub 2019 Feb 18.

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan.

Objectives: To assess the renal and non-renal efficacy of mycophenolate mofetil (MMF) in Japanese patients with systemic lupus erythematosus (SLE).

Methods: We conducted a retrospective study to assess the renal and non-renal efficacies of MMF in Japanese patients with systemic lupus erythematosus (SLE). We analyzed 14 patients with lupus nephritis (LN) who were given MMF, and 13 patients who received monthly intravenous cyclophosphamide (IVCY) as induction therapy, and a further 19 patients without LN who were treated with MMF, and 13 patients who took tacrolimus (TAC) to reduce glucocorticoid dosages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04473-wDOI Listing
February 2019
2 Reads

Quantifying in situ adaptive immune cell cognate interactions in humans.

Nat Immunol 2019 Feb 18. Epub 2019 Feb 18.

Department of Medicine, Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, USA.

Two-photon excitation microscopy (TPEM) has revolutionized the understanding of adaptive immunity. However, TPEM usually requires animal models and is not amenable to the study of human disease. The recognition of antigen by T cells requires cell contact and is associated with changes in T cell shape. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41590-019-0315-3
Publisher Site
http://dx.doi.org/10.1038/s41590-019-0315-3DOI Listing
February 2019
5 Reads

The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies.

Lupus 2019 Feb 18:961203319829825. Epub 2019 Feb 18.

2 Department of Rheumatology, State University of Rio de Janeiro, Brazil.

Objective: To analyze the impact of different classes of lupus nephritis as risk variables for maternal and fetal adverse outcomes in a cohort of pregnant lupus patients.

Methods: This is a cohort study with retrospective and prospective data collection, conducted at the University Hospital of State University of Rio de Janeiro, Brazil, from 2011 to 2016. A total of 147 pregnancies of 137 systemic lupus erythematosus patients of whom 66 had lupus nephritis were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319829825DOI Listing
February 2019
1 Read

Breaking down chronic inflammatory diseases: the role of biglycan in promoting a switch between inflammation and autophagy.

FEBS J 2019 Feb 18. Epub 2019 Feb 18.

Pharmazentrum Frankfurt/ZAFES, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität, Frankfurt am Main, Germany.

It is well established that biglycan, a small leucine-rich proteoglycan, acts as an extracellular matrix-derived danger signal in its soluble form. By binding to innate immunity Toll-like receptors (TLR) 2 and 4, biglycan initiates and perpetuates the inflammatory response. Previous work has conveyed that biglycan's role in inflammation extends far beyond its function as a canonical danger signal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.14791DOI Listing
February 2019
1 Read

Practice-Based Differences in Pediatric Discoid Lupus Erythematosus.

Br J Dermatol 2019 Feb 15. Epub 2019 Feb 15.

Northwestern University Feinberg School of Medicine, Department of Dermatology and Pediatrics, Chicago, Illinois, United States.

Background: Children with discoid lupus erythematosus (DLE) are at risk for disfigurement and progression to systemic lupus erythematosus (SLE). Consensus is lacking regarding optimal care of children with DLE.

Objectives: We compared practice patterns among pediatric dermatologists/rheumatologists treating pediatric DLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17780DOI Listing
February 2019
1 Read

Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus.

Clin Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

Section of Rheumatology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.

Elevated IL-17 levels with higher Th17 numbers are identified in systemic lupus erythematosus (SLE). STAT3 signaling plays a crucial role in the Th17 generation, and SOCS3 negatively regulates their formation. We investigated IL-17, STAT3, and SOCS3 expression, and analyzed their correlations to elucidate the regulatory mechanisms of IL-17 production in SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04467-8DOI Listing
February 2019
1 Read

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

BMC Nephrol 2019 Feb 14;20(1):53. Epub 2019 Feb 14.

Department of Pathology, Division of Renal and Transplant Pathology, Ohio State University Wexner Medical Center, M018 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH, 43210, USA.

Background: Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) is a disease entity classified under the group of "Monoclonal gammopathy-related kidney diseases", and can recur after transplant. Clinical remission of proteinuria in patients with PGNMIGD has been previously shown following anti-B cell and/or anti-plasma cell therapies. Our case is the first to show complete histologic resolution of the glomerular monoclonal IgG kappa deposits in a case of recurrent PGNMIGD in renal allograft after rituximab and steroid treatment. Read More

View Article

Download full-text PDF

Source
https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882
Publisher Site
http://dx.doi.org/10.1186/s12882-019-1239-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376770PMC
February 2019
4 Reads

Autoantibodies Against C3b-Functional Consequences and Disease Relevance.

Front Immunol 2019 29;10:64. Epub 2019 Jan 29.

INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

The complement component C3 is at the heart of the complement cascade. It is a complex protein, which generates different functional activated fragments (C3a, C3b, iC3b, C3c, C3d). C3b is a constituent of the alternative pathway C3 convertase (C3bBb), binds multiple regulators, and receptors, affecting thus the functioning of the immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361862PMC
January 2019
1 Read

Baicalin ameliorates lupus autoimmunity by inhibiting differentiation of Tfh cells and inducing expansion of Tfr cells.

Cell Death Dis 2019 Feb 13;10(2):140. Epub 2019 Feb 13.

Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.

Baicalin is a natural compound isolated from Chinese herb, which has been reported as an anti-inflammatory drug. Here, we demonstrated that Baicalin treatment could reduce urine protein, inhibit anti-ds-DNA antibody titers, and ameliorate lupus nephritis in MRL/lpr lupus-prone mice. Baicalin inhibited Tfh cell differentiation and IL-21 production, but promoted Foxp3 regulatory T cell differentiation including part of follicular regulatory T (Tfr) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1315-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374440PMC
February 2019
1 Read

Antibodies to M-type phospholipase A2 receptor (PLAR) in membranous lupus nephritis.

Lupus 2019 Mar 13;28(3):396-405. Epub 2019 Feb 13.

1 Department of Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebrón, Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: Antibodies to M-type phospholipase A2 receptor (a-PLAR) have been identified in most patients with idiopathic membranous nephropathy, but the prevalence in membranous lupus nephritis (MLN) is still unclear. The objective of this study was to assess the prevalence of a-PLAR antibodies in a large cohort of patients with lupus nephritis.

Methods: a-PLAR antibodies were measured by ELISA in serum from patients with systemic lupus erythematosus ( n = 190), of whom 37 had a biopsy-proven MLN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319828521DOI Listing
March 2019
12 Reads

Dnase1-deficient mice spontaneously develop a systemic lupus erythematosus-like disease.

Eur J Immunol 2019 Feb 13. Epub 2019 Feb 13.

Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany.

Systemic lupus erythematosus (SLE) is an autoimmune disease that has high morbidity and can result in multi-organ damage. SLE is characterized by dysregulated activation of T- and B-lymphocytes and the production of autoantibodies directed against nuclear components. The endonuclease deoxyribonuclease 1 (DNase1) is abundant in blood and a subset of SLE patients have mutations in DNASE1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201847875DOI Listing
February 2019
2 Reads

Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study.

Lupus 2019 Feb 12:961203319829827. Epub 2019 Feb 12.

1 Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Background: Lupus nephritis (LN) is a major risk factor for overall morbidity and mortality in systemic lupus erythematosus (SLE).

Methods: We retrospectively analyzed cases of proliferative and membranous LN patients who underwent a renal biopsy at our hospital in 1993-2016. We analyzed the association between complete renal response (CR) rates at 12 months after induction therapy and predictive factors for CR and their association with renal flares. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319829827DOI Listing
February 2019
1 Read

The associations of endothelial and podocyte injury in proliferative lupus nephritis: from observational analysis to in vitro study.

Lupus 2019 Mar 12;28(3):347-358. Epub 2019 Feb 12.

1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, People's Republic of China.

Our study aims to evaluate the endothelial cell-podocyte crosstalk in proliferative lupus nephritis (LN). The semi-quantification scores of glomerular endothelial cell injury and the foot process width (FPW) were processed in 110 proliferative LN patients. Podocytes were stimulated with LN-derived IgG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319828509DOI Listing
March 2019
1 Read